학술논문
The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment
Document Type
Article
Author
Babu, Sunil; Broeders, Nilufer; Lietar, Nicole; Brown, Fiona; Campbell, Philip; Chowdhury, Paramit; Kasimatis, Theo; Cirami, Lino; Caroti, Leonardo; Antognoli, Guilia; Delmas, Yahsou; Dobronravov, Vladimir; Gaeckler, Anja; Garrouste, Cyril; Greenwood, Gregory; Griffin, Siân; Huang, Chiu-Ching; Chen, I-Ru; Huang, Susan; Kim, Jin Seok; La Manna, Gaetano; Comai, Giorgia; Cappuccilli, Maria; Le Quintrec, Moglie; Jeantet, Guillaume; Fumie, Iino; Luque, Yosu; Menne, Jan; Morelle, Johan; Goffin, Eric; Muhlfeld, Anja; Nagaraj, Shashi; Arepally, Gowthami; Oh, Doyeun; Okumi, Masayoshi; Terente, Manuel Praga; Gutierréz, Elena; Rodriguez, Paola; Provot, Francois; Schönermarck, Ulf; Fischereder, Michael; Terrada, Natalia Ramos; Seitz-Polski, Barbara; Favre, Guillaume; Boyer-Suavet, Sonia; Vinogradova, Maria; Kirsanova, Tatiana; Wong, Edwin K.S.; Rondeau, Eric; Scully, Marie; Ariceta, Gema; Barbour, Tom; Cataland, Spero; Heyne, Nils; Miyakawa, Yoshitaka; Ortiz, Stephan; Swenson, Eugene; Vallee, Marc; Yoon, Sung-Soo; Kavanagh, David; Haller, Hermann
Source
In Kidney International June 2020 97(6):1287-1296
Subject
Language
ISSN
0085-2538